Revolution Medicines, Inc.
Industry Group: Pharmaceuticals
Country/Region: United States of America
Identifier: NAS:RVMD
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 672 out of 844
Universe
Global Universe 12649 out of 14915
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the non-India based rated subjects, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
Eisai Co., Ltd. |
26.5
Medium
|
247 out of 844 |
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. |
30
Medium
|
436 out of 844 |
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. |
30.3
High
|
446 out of 844 |
Aurobindo Pharma Ltd. |
32.2
High
|
511 out of 844 |
Revolution Medicines, Inc. |
35.6
High
|
672 out of 844 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Revolution Medicines, Inc.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Revolution Medicines, Inc.'s Management of ESG Material Risk is Weak